{"efta_number": "EFTA00606967", "page_count": 5, "url": "https://epstein-data.com/EFTA00606967", "pdf_url": "https://epstein-data.com/pdf/EFTA00606967.pdf", "pages": [{"efta_number": "EFTA00606967", "page_number": 0, "text_content": "41) Quest \nDiagnostics' \n—60 \nReport Status: Partial \nEPSTEIN, JEFFREY \nPatient Information \nSpecimen Information \nClient Information \nEPSTEIN, JEFFREY \nDOB: 01/20/1953 \nAGE: 63 \nGender: \nM \nPhone: \n561.366.0084 \nPatient ID: 19530120MJE \nHealth ID: 8573003290851249 \nSpecimen: \nMR911482U \nRequisition: 0021277 \nCollected: \nReceived: \nReported: \nTest Name \nLIPID PANEL \nCHOLESTEROL, TOTAL \nHDL CHOLESTEROL \nTRIGLYCERIDES \nLDL-CHOLESTEROL \n06/24/2016 \n06/27/2016 10:03 EDT \n06/27/2016 16:51 EDT \nClient #: 17436 \n56W5265 \nMOSKOWITZ, BRUCE W \nUCA/MOSKOWITZ BRUCE MD \nAttn: **P GR/UNIV.CLINICAL \n1411 N FLAGLER DR STE 7100 \nWEST PALM BEACH, FL 33401 \nIn Range \nOut Of Range \nReference Range \nLab \n184 \n125-200 mg/dL \nMI \n29 L \n> OR = 40 mg/dL \nMI \n375 H \n<150 mg/dL \nMI \n80 \n<130 mg/dL (talc) \nMI \nDesirable range <100 mg/dL for patients with CHD or \ndiabetes and <70 mg/dL for diabetic patients with \nknown heart disease. \nCHOL/HDLC RATIO \n6.3 H \nNON HDL CHOLESTEROL \n155 \nTarget for non-HDL cholesterol is 30 mg/dL higher than \nLDL cholesterol target. \nHS CRP \n1.1 \nAverage relative cardiovascular risk according to \nAHA/CDC guidelines. \nFor ages >17 \nhs-CRP mg/L \n<1.0 \n1.0-3.0 \n3.1-10.0 \n>10.0 \nYears: \nRisk According to AHA/CDC Guidelines \nLower relative cardiovascular risk. \nAverage relative cardiovascular risk. \nHigher relative cardiovascular risk. \nConsider retesting in 1 to 2 weeks to \nexclude a benign transient elevation \nin the baseline CRP value secondary \nto infection or inflammation. \nPersistent elevation, upon retesting, \nmay be associated with infection and \ninflammation. \nHONOCYSTEINE \n14.2 H \nHomocysteine is increased by functional deficiency of \nfolate or vitamin B12. Testing for methylmalonic acid \ndifferentiates between these deficiencies. Other causes \nof increased homocysteine include renal failure, folate \nantagonists such as methotrexate and phenytoin, and \nexposure to nitrous oxide. \nCOMPREHENSIVE METABOLIC \nPANEL \nGLUCOSE \n90 \n< OR = 5.0 (talc) \nmg/dL (talc) \nmg/L \n<11.4 umol/L \n65-99 mg/dL \nFasting reference interval \nUREA NITROGEN (BUN) \n24 \n7-25 mg/dL \nCREATININE \n0.99 \n0.70-1.25 mg/dL \nFor patients >49 years of age, the reference limit \nfor Creatinine is approximately 13% higher for people \nidentified as African-American. \neGFR NON-AFR. AMERICAN \n81 \n> OR = 60 mL/min/1.73m2 \nMI \nMI \nMI \nMI \nMI \nCLIENT SERVICES: 866.697.8378 \nSPECIMEN: MR911482U \nQuest. Quest Diagnostics, the associated logo and all associated Quest Diagnostics marks are the trademarks of Quest Diagnostics. \nPAGE I OF 5 \nEFTA00606967\n", "char_count": 2552}, {"efta_number": "EFTA00606967", "page_number": 1, "text_content": "rajQuest \nDiagnostics \nReport Status: Partial \nEPSTEIN, JEFFREY \nPatient Information \nSpecimen Information \nClient Information \nEPSTEIN, JEFFREY \nDOB: 01/20/1953 \nAGE: 63 \nGender: \nM \nPatient ID: 19530120MM \nHealth ID: 8573003290851249 \nSpecimen: \nMR9 I 1482U \nCollected: \n06/24/2016 \nReceived: \n06/27/2016 / 10:03 EDT \nReported: \n06/27/2016 / 16:51 EDT \nClient #: 17436 \nMOSKOWITZ, BRUCE W \nTest Name \neGFR AFRICAN AMERICAN \nBUN/CREATININE RATIO \nSODIUM \nPOTASSIUM \nCHLORIDE \nCARBON DIOXIDE \nCALCIUM \n9.6 \nPROTEIN, TOTAL \n6.8 \nALBUMIN \n4.3 \nGLOBULIN \n2.5 \nALBUMIN/GLOBULIN RATIO \n1.7 \nBILIRUBIN, TOTAL \n0.8 \nALKALINE PHOSPHATASE \n56 \nAST \n19 \nALT \n18 \nHEMOGLOBIN A1c \n6.2 H \nAccording to ADA guidelines, hemoglobin Alc <7.0% \nrepresents optimal control in non-pregnant diabetic \npatients. Different metrics may apply to specific \npatient populations. Standards of Medical Care in \nDiabetes-2013. Diabetes Care. 2013:36:s11-s66 \nIn Range \n94 \nNOT APPLICABLE \n138 \n4.3 \n104 \nOut Of \n16 L \nFor the purpose of screening for the presence of \ndiabetes \n<5.7% \n5.7-6.4% \nRange \nConsistent with the absence of diabetes \nConsistent with increased risk for diabetes \n(prediabetes) \n>or=6.5% \nConsistent with diabetes \nThis assay result is consistent with a higher risk \nof diabetes. \nCurrently, no consensus exists for use of hemoglobin \nAlc for diagnosis of diabetes for children. \nURIC ACID \n7.4 \nTherapeutic target for gout patients: <6.0 mg/dL \nTSH \nT4 (THYROXINE), TOTAL \nFREE T4 INDEX (T7) \nT3 UPTAKE \nSED RATE BY MODIFIED \nWESTERGREN \nCSC (INCLUDES DIFF/PLT) \nWHITE BLOOD CELL COUNT \nRED BLOOD CELL COUNT \nHEMOGLOBIN \nHEMATOCRIT \nMCV \nMCH \nMCHC \nRDW \nPLATELET COUNT \nMPV \nABSOLUTE NEUTROPHILS \nABSOLUTE LYMPHOCYTES \n2.26 \n7.4 \n2.4 \n32 \n9 \nReference Range \n> OR = 60 mL/min/1.73m2 \n6-22 (talc) \n135-146 mmol/L \n3.5-5.3 mmol/L \n98-110 mmol/L \n19-30 mmol/L \n8.6-10.3 mg/dL \n6.1-8.1 g/dL \n3.6-5.1 g/dL \n1.9-3.7 g/dL (talc) \n1.0-2.5 (talc) \n0.2-1.2 mg/dL \n40-115 U/L \n10-35 U/L \n9-46 U/L \n<5.7 % of total Hgb \n4.0-8.0 mg/dL \n0.40-4.50 mIU/L \n4.5-12.0 mcg/dL \n1.4-3.8 \n22-35 % \n< OR - 20 mm/h \n7.5 \n3.8-10.8 Thousand/uL \n5.24 \n4.20-5.80 Million/uL \n14.8 \n13.2-17.1 g/dL \n44.5 \n38.5-50.0 % \n84.9 \n80.0-100.0 fL \n28.2 \n27.0-33.0 pg \n33.2 \n32.0-36.0 g/dL \n14.4 \n11.0-15.0 % \n266 \n140-400 Thousand/uL \n8.0 \n7.5-11.5 fL \n4050 \n1500-7800 cells/uL \n2438 \n850-3900 cells/uL \nLab \nMI \nMI \nMI \nMI \nMI \nMI \nMI \nCLIENTSERIIICES:866.6971378 \nSPECIMEN: MR9 I 1482U \nQuest. Quest Diagnostics, the associated logo and all associated Quest Diagnostics marks are the trademarks of Quest Diagnostics. \nPAGE 2 OF 5 \nEFTA00606968\n", "char_count": 2601}, {"efta_number": "EFTA00606967", "page_number": 2, "text_content": "Quest \nDiagnostics \nReport Status: Partial \nEPSTEIN, JEFFREY \nPatient Information \nSpecimen Information \nClient Information \nEPSTEIN, JEFFREY \nDOB: 01/20/1953 \nAGE: 63 \nGender: \nM \nPatient ID: 19530120MJE \nHealth ID: 8573003290851249 \nSpecimen: \nMR911482U \nCollected: \n06/24/2016 \nReceived: \n06/27/2016 / 10:03 EDT \nReported: \n06/27/2016 / 16:51 EDT \nClient #: 17436 \nMOSKOWITZ, BRUCE W \nTest Name \nABSOLUTE MONOCYTES \nABSOLUTE EOSINOPHILS \nABSOLUTE BASOPHILS \nNEUTROPHILS \nLYMPHOCYTES \nMONOCYTES \nEOSINOPHILS \nBASOPHILS \nURINALYSIS, COMPLETE \nSee Endnote 2 \nFOLATE, SERUM \nIn Range \n480 \n495 \n38 \n54.0 \n32.5 \n6.4 \n6.6 \n0.5 \nOut Of Range \nReference Range \n200-950 cells/uL \n15-500 cells/uL \n0-200 cells/uL \n12.7 \nng/mL \nReference Range \nLow: \n<3.4 \nBorderline: \n3.4-5.4 \nNormal: \n>5.4 \nC-REACTIVE PROTEIN \n0.10 \n<0.80 mg/dL \nPlease be advised that patients taking Carboxypenicillins \nmay exhibit falsely decreased C-Reactive Protein levels \ndue to an analytical interference in this assay. \nPROLACTIN \n3.7 \nTESTOSTERONE, TOTAL, \nMALES (ADULT), IA \n149 L \nMen with clinically significant hypogonadal symptoms \nand testosterone values repeatedly less than \napproximately 300 ng/dL may benefit from testosterone \ntreatment after adequate risk and benefits counseling. \nIn hypogonadal males, Testosterone, Total, LC/MS/MS, \nis the recommended assay due to the diminished \naccuracy of immunoassay at levels below 250 ng/dL. \nThis test code (15983) must be collected in a \nred-top tube with no gel. Two morning (8-10 a.m.) \nspecimens obtained on different days are recommended \nby The Endocrine Society for screening for \nhypogonadism. \nPSA, TOTAL \n0.5 \nEndnote 1 \nThis test was performed using the Siemens \nchemiluminescent method. Values obtained from \ndifferent assay methods cannot be used \ninterchangeably. PSA levels, regardless of \nvalue, should not be interpreted as absolute \nevidence of the presence or absence of disease. \n* Test not performed. \n* No specimen received. \n* \n* \n2.0-18.0 ng/mL \n250-827 ng/dL \n< OR = 4.0 ng/mL \nLab \nMI \nMI \nMI \nMI \nMI \nMI \nCLIENT SERVICES: 866.697.8378 \nSPECIMEN: MR911482U \nQuest. Quest Diagnostics, the associated logo and all associated Quest Diagnostics marks are the trademarks of Quest Diagnostics. \nPAGE30F5 \nEFTA00606969\n", "char_count": 2266}, {"efta_number": "EFTA00606967", "page_number": 3, "text_content": "rajQuest \nDiagnostics \nReport Status: Partial \nEPSTEIN, JEFFREY \nPatient Information \nSpecimen Information \nClient Information \nEPSTEIN, JEFFREY \nDOB: 01/20/1953 \nAGE: 63 \nGender: \nM \nPatient ID: 19530120MJE \nHealth ID: 8573003290851249 \nSpecimen: \nMR911482U \nCollected: \n06/24/2016 \nReceived: \n06/27/2016 / 10:03 EDT \nReported: \n06/27/2016 / 16:51 EDT \nClient #: 17436 \nMOSKOWITZ. BRUCE W \nEndocrinology \nTest Name \nResult \nReference Range \nLab \nVITAMIN D,25.OH,TOTAL,IA \n36 \n30-100 ng/mL \nMI \nVitamin D Status \nDeficiency: \nInsufficiency: \nOptimal: \n25-OH Vitamin D: \n<20 ng/mL \n20 - 29 ng/mL \n> or = 30 ng/mL \nFor 25-OH Vitamin D testing on patients on \nD2-supplementation and patients for whom quantitation \nof D2 and D3 fractions is required, the QuestAssureD(TM) \n25-OH VIT D, (D2,D3), LC/MS/MS is recommended: order \ncode 92888 (patients >2yrs). \nFor more information on this test, go to: \nhttp://education.questdiagnostics.com/faq/FAQ163 \n(This link is being provided for \ninformational/educational purposes only.) \nPhysician Comments: \nInfectious Diseases \nTest Name \nResult \nReference Range \nLab \nHIV 1/2 ANTIGEN/ANTIBODY, FOURTH GENERATION W/RFL \nMI \nHIV AG/AB, 4TH GEN \nI \nNON-REACTIVE \nI NON-REACTIVE \nHIV-1 antigen and HIV-1/HIV-2 antibodies were not \ndetected. There is no laboratory evidence of HIV \ninfection. \nPLEASE NOTE: This information has been disclosed to \nyou from records whose confidentiality may be \nprotected by state law. If your state requires such \nprotection, then the state law prohibits you from \nmaking any further disclosure of the information \nwithout the specific written consent of the person \nto whom it pertains, or as otherwise permitted by law. \nA general authorization for the release of medical or \nother information is NOT sufficient for this purpose. \nFor additional information please refer to \nhttp://education.questdiagnostics.com/faq/FAQ106 \n(This link is being provided for informational/ \neducational purposes only.) \nThe performance of this assay has not been clinically \nvalidated in patients less than 2 years old. \nCLIENTSERVICES:866.697.8378 \nSPECIMEN: MR911482U \nPAGE 4 OF 5 \nQuest. Quest Diagnostics, the associated logo and all associated Quest Diagnostics marks are the trademarks of Quest Diagnostics. \nEFTA00606970\n", "char_count": 2280}, {"efta_number": "EFTA00606967", "page_number": 4, "text_content": "rajQuest \nDiagnostics \nReport Status: Partial \nEPSTEIN, JEFFREY \nPatient Information \nSpecimen Information \nEPSTEIN, JEFFREY \nSpecimen: \nMR911482U \nCollected: \n06/24/2016 \nDOB: 01/20/1953 \nAGE: 63 \nReceived: \n06/27/2016 / 10:03 EDT \nGender: \nM \nReported: \n06/27/2016 / 16:51 EDT \nPatient ID: 19530120MJE \nHealth ID: 8573003290851249 \nInfectious Diseases \nClient Information \nClient #: 17436 \nMOSKOWITZ, BRUCE W \nTest Name \nResult \nReference Range \nLab \nPhysician Comments: \nInfectious Diseases \nTest Name \nResult \nReference Range \nLab \nHEPATITIS PANEL, ACUTE W/REFLEX TO CONFIRMATION \nHEPATITIS A IGM \nI \nNON-REACTIVE \nI NON-REACTIVE \nMI \nHEPATITIS B SURFACE ANTIGEN W/REFL CONFIRM \nMI \nHEPATITIS B SURFACE ANTIGEN \nNON-REACTIVE \nNON-REACTIVE \nHEPATITIS B CORE ANTIBODY (IGM) \nNON-REACTIVE \nNON-REACTIVE \nMI \nHEPATITIS CAB W/REFL TO HCV RNA, ON, PCR \nMI \nHEPATITIS C ANTIBODY \nNON-REACTIVE \nNON-REACTIVE \nSIGNAL TO CUT-OFF \n0.02 \n<1.00 \nPhysician Comments: \nPENDING TESTS: \nTESTOSTERONE, FREE LC/MS/MS \nPERFORMING SITE: \nMI \nQUEST DIAGNOSTICS.NIIAMI. I0RI0 COMMERCE PARKWAY. MIRAMAR. FL 3.360-5.3938 Laboraumy DINCIOI: GLEN L. NORM MD PHD. WA: I 0D0277334 \nCLIENT SERVICES: \nSPECIMEN: MR911482U \nQuest. Quest Diagnostics, the associated logo and all associated Quest Diagnostics marks are the trademarks of Quest Diagnostics. \nPAGE 5 OF 5 \nEFTA00606971\n", "char_count": 1353}]}